1
Home
Companies

Oncotelic Therapeutics

Oncotelic Therapeutics
Leadership team

Dr. Chulho Park Ph.D. (Consultant)

Mr. Amit Shah (Chief Financial Officer)

Dr. Vuong Trieu Ph.D. (Chairman & CEO)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Los Angeles, California, United States
Established
1988
Company Registration
SEC CIK number: 0000908259
Net Income
5M - 20M
Traded as
OTCQB:OTLC
Social Media
URL
https://www.oncotelic.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
History

Oncotelic Therapeutics was founded in 2019 as a spin-off from the Mayo Clinic in order to develop precision immunotherapy treatments for cancer. The company’s TAC (Tumor-Associated Antigen-Coated) platform is designed to combine the precision of therapeutic antibodies with the expanded potency of cellular immunotherapy.

Mission
Our mission is to offer personalized, targeted, and off-the-shelf cancer therapies across the globe.
Vision
Our vision is to save thousands of lives by developing powerful, previously undiscovered immunotherapies for cancer and other diseases.
Key Team

Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. (Chief Clinical Officer of Translational Medicine & Director)

Mr. Saranjit Saund (CBO & GM of AI Division)

Dr. Larn Hwang (Chief Scientific Officer)

Dr. Fatih M. Uckun M.D., Ph.D. (Chief Medical Officer)

Dr. Seymour Howard Fein M.D. (Chief Regulatory Officer)

Mr. Burcak Beser (CTO of AI Division)

Recognition and Awards
Oncotelic was awarded the Mayo Clinic Early Stage Investing’s ‘Best Idea’ award in 2019, as well as the Cataract Capital Biotech Award in 2020.
References

https://in.investing.com/equities/oxigene-dividends

https://finance.yahoo.com/quote/OTLC/profile?p=OTLC

https://www.crunchbase.com/organization/oxigene

https://www.oncotelic.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Oncotelic Therapeutics
Leadership team

Dr. Chulho Park Ph.D. (Consultant)

Mr. Amit Shah (Chief Financial Officer)

Dr. Vuong Trieu Ph.D. (Chairman & CEO)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Los Angeles, California, United States
Established
1988
Company Registration
SEC CIK number: 0000908259
Net Income
5M - 20M
Traded as
OTCQB:OTLC
Social Media
URL
https://www.oncotelic.com